- 客服:
- 电话: 13061953619
- 微信:
Lenzilumab (KB 003) 是一种靶向 CSF2/GM-CSF 的人源化单克隆抗体,可用于 COVID-19、慢性粒单核细胞白血病 (CMML) 和幼年粒单核细胞白血病 (JMML) 研究。
Lenzilumab (KB 003) is a humanized monoclonal antibody targeting CSF2/GM-CSF for COVID-19, chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) studies[1][2].
Lenzilumab (i.p., 10 mg/kg, daily, 10 days) inhibits GM-CSF without inhibiting the cellular function of CAR-T and enhances its antitumor activity in NSG mice[1].
Animal Model: | NSG mice with CART19 cells[1] |
Dosage: | 10 mg/kg |
Administration: | Intraperitoneal injection; daily; 10 days |
Result: | Neutralized GM-CSF, had antitumor activity and improved the proliferation of cytokine release syndrome (CRS) and neuroinflammation (NI). |
[1]. Rosalie M Sterner, et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood. 2019 Feb 14;133(7):697-709.
[2]. Zelalem Temesgen, et al. GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia: A Case-Cohort Study. Mayo Clin Proc. 2020 Nov;95(11):2382-2394.
动态评分
0.0